Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Leap Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
pharmaand GmbH
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc